Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;18(11):679-695.
doi: 10.1038/s41571-021-00524-x. Epub 2021 Jun 30.

Nasopharyngeal carcinoma: an evolving paradigm

Kenneth C W Wong  1 , Edwin P Hui  1 , Kwok-Wai Lo  2 , Wai Kei Jacky Lam  3 , David Johnson  1 , Lili Li  1 , Qian Tao  1 , Kwan Chee Allen Chan  3 , Ka-Fai To  2 , Ann D King  4 , Brigette B Y Ma  5 , Anthony T C Chan  6
Affiliations
Review

Nasopharyngeal carcinoma: an evolving paradigm

Kenneth C W Wong et al. Nat Rev Clin Oncol. 2021 Nov.

Abstract

The past three decades have borne witness to many advances in the understanding of the molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated cancer endemic to southern China, southeast Asia and north Africa. In this Review, we provide a comprehensive, interdisciplinary overview of key research findings regarding NPC pathogenesis, treatment, screening and biomarker development. We describe how technological advances have led to the advent of proton therapy and other contemporary radiotherapy approaches, and emphasize the relentless efforts to identify the optimal sequencing of chemotherapy with radiotherapy through decades of clinical trials. Basic research into the pathogenic role of EBV and the genomic, epigenomic and immune landscape of NPC has laid the foundations of translational research. The latter, in turn, has led to the development of new biomarkers and therapeutic targets and of improved approaches for individualizing immunotherapy and targeted therapies for patients with NPC. We provide historical context to illustrate the effect of these advances on treatment outcomes at present. We describe current preclinical and clinical challenges and controversies in the hope of providing insights for future investigation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). - PubMed - DOI
    1. Ferlay, J. et al. Data visualization tools for exploring the global cancer burden in 2020. Cancer Today https://gco.iarc.fr/today (WHO, International Agency for Research on Cancer, 2018).
    1. Lee, A. W. et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int. J. Cancer 103, 680–685 (2003). - PubMed - DOI
    1. Yu, M. C. & Yuan, J. M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 421–429 (2002). - PubMed - DOI
    1. Carioli, G. et al. Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: focus on low-risk areas. Int. J. Cancer 140, 2256–2264 (2017). - PubMed - DOI

Publication types

LinkOut - more resources